Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD P 506 A with red light photodynamic therapy for actinic keratosis
2005-003555-13Phase 3Completed
- Sponsor
- photonamic GmbH & Co. KG
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of 5-aminolevulinic acid in actinic keratosis (AK) (2 arms), sponsored by photonamic GmbH & Co. KG. Primary endpoints: Complete clinical clearance rate of treated actinic keratosis lesions at 12 weeks and Complete clinical clearance rate on patient basis at 12 weeks. Started Feb 2006; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2005-003555-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003555-13.